Free Trial
NASDAQ:SBFM

Sunshine Biopharma Q1 2025 Earnings Results & Report

Sunshine Biopharma logo
$2.61 -0.09 (-3.33%)
As of 03:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Sunshine Biopharma reported Q1 2025 earnings on May 15, 2025. The company reported EPS of -$88.00, while revenue was $8.90 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
After Market Closes

Sunshine Biopharma EPS Results

Actual EPS
-$88.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 6 quarters

Sunshine Biopharma Revenue Results

Actual Revenue
$8.90 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Sunshine Biopharma Q1 2025 Earnings FAQ

Sunshine Biopharma (NASDAQ:SBFM) reported earnings of -$88.00 per share for Q1 2025. The report was announced on Thursday, May 15, 2025.

Sunshine Biopharma reported revenue of $8.90 million for Q1 2025.

Sunshine Biopharma Earnings Headlines

Sunshine Biopharma (SBFM) Set to Post Quarterly Earnings on Thursday
Sunshine Biopharma (SBFM) AI Stock Analysis
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Sunshine Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sunshine Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sunshine Biopharma and other key companies, straight to your email.

About Sunshine Biopharma

Sunshine Biopharma (NASDAQ:SBFM) is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors.

In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations. The company has been associated with the distribution and commercialization of prescription and over-the-counter products in Canada, including generic medicines and other healthcare products.

Sunshine Biopharma is headquartered in Canada and has conducted its pharmaceutical and biotechnology activities primarily through its Canadian operations. The company has identified Steve Slilaty as its chief executive officer and has traded on the Nasdaq Capital Market under the symbol SBFM. Its business combines the development of proprietary oncology candidates with pharmaceutical product commercialization.

View Sunshine Biopharma Profile